Stock Groups

AstraZeneca to create separate division for vaccines, antibody therapies -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – A vial AstraZeneca vaccination for coronavirus (COVID-19), taken at one of Egypt’s Youth Centres, where people can obtain the vaccines free of registration. The aim of this initiative is to improve the country’s vaccination drive.

(Reuters) -AstraZeneca is creating a separate division for vaccines and antibody therapies to be led by senior executive Iskra Reić, the drugmaker said on Tuesday, as it builds focus on its COVID-19 shot and development of coronavirus treatments.

Reuters reported July that Anglo Swedish company had begun exploring potential options for its vaccination business. It expects to gain more insight by the year 2021.

A spokesperson for the new unit stated that it will include research, development, manufacturing and commercial teams as well as medical and surgical personnel.

He said that the team would be devoted to COVID-19, our long-acting antigen combination, and to developing vaccines to address multiple forms of concern as well as our portfolio for respiratory virus disease.

Financial Times first reported the news.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from relying on data including charts, buy/sell signals, and quotes. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]